13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001583977
Total reported value
$2.0B
$2.0B
42 檔
34.6%
According to the latest 13F quarterly dataset, Cormorant Asset Management, LP managed an equity portfolio of $2.0B at the end of Q2 2025, spanning 42 distinct U.S. exchange-listed positions.
In Q2 2025, Cormorant Asset Management, LP adopted a defensive or profit-taking posture, trimming 16 positions and completely liquidating 3 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 29.86% | -0.99% | — | |
| 2 | EYPT | Eyepoint Inc | Stock-Other | 5.84% | -0.22% | — | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 5.15% | -1.07% | -20.00% | |
| 4 | PRAX | Praxis Precision Medicines I | Stock-Other | 5.09% | -3.35% | -6.88% | |
| 5 | ✓ | Merus N V | Stock-Other | 4.39% | — | +51.35% | |
| 6 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.15% | +0.07% | +3.66% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 4.05% | -1.15% | +2.86% | |
| 8 | ACLXGBX | Arcellx Inc | Stock-Other | 3.92% | — | -23.81% | |
| 9 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.93% | -0.66% | -29.27% | |
| 10 | JANX | Janux Therapeutics Inc | Stock-Other | 2.58% | — | -30.23% | |
| 11 | RAPP | Rapport Therapeutics Inc | Stock-Other | 2.49% | +1.02% | — | |
| 12 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.47% | — | — | |
| 13 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 2.30% | — | — | |
| 14 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.06% | -0.64% | — | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.04% | -2.09% | EXIT | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 1.91% | -0.09% | -0.80% | |
| 17 | GHRS | GH Research PLC | Stock-Other | 1.82% | — | — | |
| 18 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.43% | — | -31.25% | |
| 19 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.22% | +0.02% | — | |
| 20 | ABVX | Abivax Sa-adr | Stock-Other | 1.21% | +0.36% | — | |
| 21 | CGON | Cg Oncology Inc | Stock-Other | 1.21% | — | -19.35% | |
| 22 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.04% | -0.29% | -25.93% | |
| 23 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.04% | — | — | |
| 24 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.91% | -0.47% | -25.00% | |
| 25 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.86% | -0.22% | -33.33% | |
| 26 | ✓ | Stock-Other | 0.85% | — | — | ||
| 27 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.81% | — | — | |
| 28 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.78% | -0.42% | EXIT | |
| 29 | BIOA | Bioage Labs Inc | Stock-Other | 0.66% | +0.46% | -18.59% | |
| 30 | ✓ | Engene Holdings Inc | Stock-Other | 0.63% | — | — | |
| 31 | MBX | Mbx Biosciences Inc | Stock-Other | 0.59% | -0.12% | — | |
| 32 | CABA | Cabaletta Bio Inc | Stock-Other | 0.57% | +0.06% | — | |
| 33 | ALMS | Alumis Inc | Stock-Other | 0.48% | +0.37% | — | |
| 34 | BMEA | Biomea Fusion Inc | Stock-Other | 0.48% | — | — | |
| 35 | KRRO | Korro Bio Inc | Stock-Other | 0.43% | — | +22.27% | |
| 36 | PCVX | Vaxcyte Inc | Stock-Other | 0.42% | -0.14% | — | |
| 37 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.42% | — | -50.00% | |
| 38 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.30% | +0.39% | NEW | |
| 39 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 40 | KALAEUR | Kala Bio Inc | Stock-Other | 0.21% | — | — | |
| 41 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.17% | — | — | |
| 42 | BHVN | Biohaven Ltd. | Stock-Other | 0.01% | +1.24% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | +4.9% | — | Unchanged |
| 2 | VRNA | Verona Pharma PLC - Adr | +2.5% | NEW | New buy |
| 3 | EYPT | Eyepoint Inc | +2.5% | — | Unchanged |
| 4 | ✓ | Merus N V | +2.1% | +51.35% | Add |
| 5 | INSM | Insmed Inc | +1% | +2.86% | Add |
| 6 | CABA | Cabaletta Bio Inc | +0.6% | NEW | New buy |
| 7 | AARD | Aardvark Therapeutics Inc | +0.4% | — | Unchanged |
| 8 | RAPP | Rapport Therapeutics Inc | +0.3% | — | Unchanged |
| 9 | CRBP | Corbus Pharmaceuticals Holdi | +0.3% | — | Unchanged |
| 10 | ABVX | Abivax Sa-adr | +0.2% | — | Unchanged |
| 11 | MBX | Mbx Biosciences Inc | +0.2% | — | Unchanged |
| 12 | PHVS | Pharvaris N.V. | +0.2% | -0.80% | Trim |
| 13 | VYNE | Vyne Therapeutics Inc | +0.2% | NEW | New buy |
| 14 | GHRS | GH Research PLC | +0.2% | — | Unchanged |
| 15 | PRAX | Praxis Precision Medicines I | +0.1% | -6.88% | Trim |
| 16 | STOK | Stoke Therapeutics Inc | +0.1% | — | Unchanged |
| 17 | ✓ | 0% | — | Unchanged | |
| 18 | CRGX | Cargo Therapeutics Inc | 0% | — | Unchanged |
| 19 | BHVN | Biohaven Ltd. | 0% | — | Unchanged |
| 20 | KALAEUR | Kala Bio Inc | -0.1% | — | Unchanged |
| 21 | BBIO | Bridgebio Pharma Inc | -0.1% | -20.00% | Trim |
| 22 | ELVN | Enliven Therapeutics Inc | -0.1% | -20.00% | Trim |
| 23 | KRRO | Korro Bio Inc | -0.1% | +22.27% | Add |
| 24 | BIOA | Bioage Labs Inc | -0.1% | -18.59% | Trim |
| 25 | SPRY | Ars Pharmaceuticals Inc | -0.1% | -31.25% | Trim |
| 26 | PCVX | Vaxcyte Inc | -0.1% | — | Unchanged |
| 27 | BMEA | Biomea Fusion Inc | -0.1% | — | Unchanged |
| 28 | ✓ | Engene Holdings Inc | -0.2% | — | Unchanged |
| 29 | ✓ | Helix Acquisition CORP Ii | -0.2% | — | Unchanged |
| 30 | CGON | Cg Oncology Inc | -0.2% | -19.35% | Trim |
| 31 | PLRX | Pliant Therapeutics Inc | -0.3% | EXIT | Sold out |
| 32 | 260 | Centessa Pharmaceuticals-adr | -0.4% | -7.74% | Trim |
| 33 | RNAGBP | Avidity Biosciences Inc | -0.5% | -50.00% | Trim |
| 34 | ALMS | Alumis Inc | -0.5% | — | Unchanged |
| 35 | ARQT | Arcutis Biotherapeutics Inc | -0.6% | -25.93% | Trim |
| 36 | OKUR | Onkure Therapeutics Inc-a | -0.6% | EXIT | Sold out |
| 37 | RYTM | Rhythm Pharmaceuticals Inc | -0.6% | EXIT | Sold out |
| 38 | TARS | Tarsus Pharmaceuticals Inc | -0.6% | -25.00% | Trim |
| 39 | CRNX | Crinetics Pharmaceuticals In | -0.7% | -33.33% | Trim |
| 40 | DRUG | Bright Minds Biosciences Inc | -0.8% | — | Unchanged |
| 41 | ACLXGBX | Arcellx Inc | -1.3% | -23.81% | Trim |
| 42 | AXSM | Axsome Therapeutics Inc | -1.4% | -60.00% | Trim |
| 43 | JANX | Janux Therapeutics Inc | -1.8% | -30.23% | Trim |
| 44 | NAMS | NewAmsterdam Pharma Company N.V. | -1.8% | -29.27% | Trim |
| 45 | EWTX | Edgewise Therapeutics Inc | -2.6% | +3.66% | Add |
According to official SEC Form 13F filings, Cormorant Asset Management, LP reported a total U.S. public equity portfolio value of $2.0B across 42 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MLTX, EYPT, BBIO) accounted for 34.6% of total reported equity market value during Q2 2025.
Top New Position Initiated
VRNA
市值: $33.1M
Top Position Liquidated / Trimmed
RYTM
前期市值: $7.9M
During Q2 2025, Cormorant Asset Management, LP's top holdings by market value included MLTX (29.9%)、EYPT (5.8%)、BBIO (5.2%). The largest single position, MLTX, represented 29.9% of total portfolio value.
In Q2 2025, Cormorant Asset Management, LP made 26 total portfolio adjustments, initiating 3 new buys, adding to 4 positions, trimming 16 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.